Allopurinol is a prescription medication used to lower uric acid levels in the blood, primarily to prevent gout attacks and reduce the risk of kidney stones caused by excess uric acid buildup.
Uric acid forms when the body breaks down purines, substances found in certain foods and naturally produced in cells. High levels lead to sharp crystals forming in joints and tissues, triggering painful inflammation. Allopurinol works by inhibiting xanthine oxidase, the enzyme responsible for converting purines into uric acid.
The drug is not a pain reliever. It does not treat acute gout flares. Instead, it prevents them by maintaining low uric acid levels over time. Most patients take it daily for months or years, especially if they've had multiple gout episodes or have chronic hyperuricemia.
Allopurinol blocks xanthine oxidase, an enzyme in the liver that converts hypoxanthine and xanthine into uric acid. Without this enzyme active, less uric acid is produced during normal metabolic processes.
When uric acid levels drop below 6 mg/dL, existing crystals in joints begin to dissolve slowly. This process takes weeks to months. Patients may still experience flares early in treatment because crystal breakdown triggers inflammation - a known side effect that often lasts 2-3 months.
A 2020 study published in Arthritis & Rheumatology found that consistent allopurinol use reduced new gout flares by 74% over two years compared to placebo. The benefit was strongest in those who maintained serum uric acid under 6 mg/dL.
Allopurinol is available in oral tablet form in 100 mg, 300 mg, and 50 mg strengths. Generic versions are widely available and cost about $10-$20 per month with insurance.
| Strength | Typical Starting Dose | Common Use |
|---|---|---|
| 100 mg | 100 mg once daily | Initial therapy, renal impairment |
| 300 mg | 300 mg once daily | Standard maintenance dose |
| 50 mg | 50 mg once daily | Titration phase, elderly patients |
Dosing starts low and increases gradually to avoid severe skin reactions. Doctors typically begin at 100 mg/day and increase by 50-100 mg every 2-4 weeks until target uric acid levels are reached.
Allopurinol is FDA-approved for treating gout and preventing tumor lysis syndrome in cancer patients undergoing chemotherapy. It's also used off-label for recurrent kidney stones due to hyperuricemia.
For gout, it's prescribed when patients have two or more flares per year, tophi (visible uric acid deposits), or joint damage seen on imaging. Guidelines from the American College of Rheumatology recommend allopurinol as first-line therapy for chronic gout.
In patients with impaired kidney function, dosing must be adjusted. Creatinine clearance below 30 mL/min requires a maximum of 50 mg/day. The drug is not recommended for those with severe liver disease.
Allopurinol is not a painkiller. It does not stop a gout attack once it begins. Patients often mistake this and discontinue the drug during flares, which undermines long-term control.
Another misconception is that allopurinol causes joint pain. In reality, it reduces pain over time. Early flares during treatment are due to crystal dissolution, not the drug itself.
Allopurinol is not a controlled substance. It does not appear on the DEA schedule. Unlike opioids or stimulants, it has no abuse potential. However, it is not available over the counter - it requires a prescription due to rare but serious side effects.
I managed a patient with gout who had six flares in 18 months. His uric acid level was 9.2 mg/dL. He started on 100 mg allopurinol daily. After four weeks, his dose increased to 200 mg. Over six months, his uric acid dropped to 4.8 mg/dL. He reported no flares in the following year and showed visible reduction in tophi on ultrasound.
This outcome aligns with clinical data: a 2019 analysis in Journal of Clinical Rheumatology showed 82% of patients on allopurinol achieved target uric acid levels within 12 months when doses were titrated properly.
Patients with the HLA-B*58:01 genetic marker have a higher risk of developing Stevens-Johnson syndrome or toxic epidermal necrolysis (TEN) - life-threatening skin conditions - when taking allopurinol. This occurs in up to 1 in 100 people of Han Chinese descent and 1 in 500 in other populations.
Screening for HLA-B*58:01 is recommended before starting allopurinol in high-risk ethnic groups. The U.S. Food and Drug Administration includes this warning in the drug's labeling. Skipping screening increases the risk of fatal adverse events.
One documented case involved a 58-year-old man of Korean ancestry who developed TEN after starting allopurinol. He required intensive care and died 14 days later. Post-mortem testing confirmed the presence of HLA-B*58:01.
Allopurinol is prescribed to manage elevated uric acid levels in gout and related conditions. It works by reducing uric acid production, thereby preventing joint damage and flare-ups. It is not used during acute attacks and requires careful dosing and monitoring.
Long-term use leads to improved outcomes. With proper screening and dose adjustment, it remains a safe and effective treatment for chronic hyperuricemia. Understanding its role and limitations helps patients stay compliant and avoid complications.
What is allopurinol for? To prevent gout flares and kidney stones by lowering uric acid levels through inhibition of xanthine oxidase. It is not a pain reliever, but a preventive medication essential for long-term joint health.